Future clinical trials using agents that target Bcl-2 and/or Bag-1 in breast cancer should focus on hormone receptor-positive patients, and all studies should incorporate assessment of target expression in pretreatment tumors to assess the association between target expression and response to therapy. The gene discussed is BCL2; the disease is breast cancer.